IMUX

7.0654.40%
JN

Jorg Neermann

Independent Director

Dr. Jorg Neermann, also known as Joerg, Ph.D., is Member of the Supervisory Board of numares AG. He also known as Joerg, Ph.D. was Venture Partner of Vorwerk Ventures since 2023. In 2021 and 2022 he served as CEO of the Göttingen based longevity start-up Curexsys. He was Director at Imcyse SA since 2019 until January 2021. In 2007 he joined LSP Life Sciences Partners as a Partner in their Munich office and was Managing Director of LSP's German subsidiary until 2020. Mr. Neermann's prime focus and responsibility within LSP is to invest in unlisted securities. He got strong scientific background and hands-on finance and investment expertise to the LSP team. Mr. Neermann gained experience in the international venture capital business in the field of life science since 1996. He was the Managing Partner of Deutsche Venture Capital, where he ran its healthcare investment franchise and was responsible for numerous early and late stage life science investments across Europe, leading to more than ten successful exit transactions, including IPOs, trade and asset sales. Prior to joining Deutsche Venture Capital as an Investment Manager in 1998, he opened the Munich office and was appointed as a Partner in January 2000. In July 2001, Mr. Neermann was appointed as Senior Partner and since January 2002, he was a Managing Partner responsible for the overall investment strategy and investment. He started his venture capital career in 1996 at Atlas Venture L.P. as a key member of the international life sciences team. During his tenure as a Ph.D. student at the German National Research Institute for Biotechnology (GBF, now Helmholtz Center for Infection Research), Mr. Neermann worked for a strategic management consultancy firm. He has been Independent Director of Immunic, Inc. since April 2019. He was the Chairman of the Supervisory Board at Immunic AG. He served as Chairman of Supervisory Board of 4SC AG until May 31, 2012 and served as its Member of Supervisory Board from August 2000 to May 31, 2012. He served as Vice Chairman of Supervisory Board of KeyNeurotek Pharmaceuticals AG. He had been a Member of Supervisory Board at Vivoryon Therapeutics N.V. (formerly known as Vivoryon Therapeutics AG & Probiodrug AG) since 2011 and served as its Non-Executive Director until May 2023. He serves as a Member of the Supervisory Board at Curetis Gmbh (formerly known as Curetis AG). He serves as a Director of Vivendy Therapeutics Ltd. He serves as a Member of Supervisory Board of Vectura GmbH. He serves as a Director of Keyneurotek AG. He serves as a Member of Supervisory Board at Activaero GmbH. He served as a Director of Kuros Biosciences AG from 2016 to May 22, 2017. He served as a Member of Supervisory Board at Affimed N.V. since March 2008. He served as Non-Executive Director of Nextgen Group PLC from September 2007 to January 29, 2009. He served as Non-Executive Director of NextGen Sciences, Inc. He served as Observer of Vivoryon Therapeutics AG (formerly known as Probiodrug AG). He served as a Director of TopoTarget Germany AG, VGG Venture Capital GmbH, Switch Biotech GmbH, Biopsytec Holding AG, Igeneon GmbH, G2M AG, Cardion AG, Evotec (Göttingen) AG, Affimed N.V and Avontec GmbH. He served as Member of Supervisory Board at Curetis N.V. He served as a Director of Topotarget A/s from March 2005 to April 6, 2006. He served as Member of Supervisory Board at Epigenomics AG until April 9, 2005. Mr. Neermann holds an M.S. and a Ph.D. degree in Biotechnology (1987 - 1996) from the Technical University of Braunschweig, Germany. He studied Biotechnology and Economics at Braunschweig University, M.I.T. and Harvard Business School.

Positions